Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen Acquires Exclusive License to Metastatic Colon Cancer Biomarker

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it has acquired the exclusive rights to use a specific microRNA as a biomarker for predicting patient outcomes in metastatic colorectal cancer.

The license was obtained from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique — Hopitaux de Paris. Terms of the deal were not disclosed.

The miRNA, hsa-miR-31-3p, has been shown to predict progression-free survival in wild-type KRAS patients with the disease who receive treatment with anti-epidermal growth factor receptor drugs, the company said.

"This agreement increases IntegraGen's proprietary oncology biomarker portfolio and enhances our ability to offer new molecular diagnostic tests to physicians which can assist their clinical management of cancer patients," IntegraGen CEO Bernard Courtieu said in a statement.

The license is based on the work of a researcher from the European Georges Pompidou Hospital University Paris Descartes.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.